** Medical device maker Nevro Corp's shares rise 18.6% to $6.31 premarket

** On Monday, co posted Q3 revenue of $96.9 mln vs analysts' est. of $93.1 mln - data compiled by LSEG

** Co reported Q3 loss per share of 41 cents vs est. for loss of 81 cents per share

** Expects 2024 adj. EBITDA loss of $16 mln to $18 mln, smaller than earlier forecast for loss of $18 mln to $20 mln

** As of last close, stock had fallen ~75% YTD, as NVRO has struggled with weak demand for some of its products and had earlier cut its revenue forecast

** J.P. Morgan says Nevro's management expects outlook to improve in 2025, but brokerage views Nevro as "a 'show me' story" as it tries to reach breakeven

** Twelve of 16 brokerages rate the stock "hold" and 4 "sell" or lower; median PT is $6.50 - LSEG data

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))